Meeting
2021 ASCO Annual Meeting
A phase II study of anlotinib combined with STUPP regimen in the treatment of patients with newly diagnosed glioblastoma (GBM).
Authors
Peijing Li
Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China
Peijing Li , Yuan yuan Yuan Chen , Shuzhen Lai , Fagui Jiang , Xiaohui Liu , Changjuan Tao , Lei Wang , Guihong Liu , Jing Huang , Yiqiang Tang , Zhigang Liu , Guoping Shen , Chaoming Li , Tieming Xie , Fangxiao Lu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Clinical Trial Registration Number
NCT04119674
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 2039)
DOI
10.1200/JCO.2021.39.15_suppl.2039
Abstract #
2039
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A randomized phase II study of anlotinib combined with STUPP versus STUPP alone in patients with newly diagnosed glioblastoma (GBM).
First Author: Yuan yuan Yuan Chen
Poster
2021 ASCO Annual Meeting
Preliminary results of the abemaciclib arm in the Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A phase II platform trial using Bayesian adaptive randomization.
First Author: Eudocia Quant Lee
Poster
2021 ASCO Annual Meeting
Combination of sintilimab, anlotinib and pegaspargase "sandwich" with radiotherapy in localized natural killer/T cell lymphoma: A multicenter, phase 2 study.
First Author: Zhiming Li
Poster
2017 ASCO Annual Meeting
Activity of cabazitaxel in temozolomide refractory glioblastoma: Final results of a phase 2 study (C-GBM study; EudraCT 2013-001550-98 NCT 01866449).
First Author: Bernhard Heinrich